Comorbidities and its relation to performance status and estimated survival rate among cancer patients

N.A.

Article Details

Comorbidities and its relation to performance status and estimated survival rate among cancer patients

Authors:

N.A.

Publisher:

Marmara University

Main Topics:

Pharmaceutical Sciences | Clinical Pharmacology and Therapeutics | Basic Pharmacology

Journal:

Journal of Research in Pharmacy Vol.23 Issue 2, pp.304-314

Document Type:

Article

Publication Date:

6/2025

Document Language:

English

Document ID (Org No.):

2001346487

pISSN:

2630-6344

Keywords:

Abstract:

 Many studies report the presence of comorbidities, which have a consequential impact on the management and survival of cancer patients. The aim of the present study is to assess the prevalence of comorbidities and their influence on overall management, estimated survival, and performance of cancer patients. A hospital based prospective study was conducted at a multi-specialty teaching hospital for a period of 10 months. Out of a sample of 140 cancer patients, 70 were diagnosed with comorbidities. Estimated survival rates and comorbidity scores were assessed using the Charlson Comorbidity Index CCI. Performance scores were observed using the Eastern Cooperative Oncology Group ECOG performance score. CCI and performance score were statistically analyzed by SPSS Version 19. Hypertension 40 was the leading comorbidity, followed by diabetes 25.71. Those women with high 5 CCI score 57.14, p0.04 had significantly decreased estimated survival rates of less than or equal to 2 months compared to those having less than  2 CCI score and who reached estimated survival rates of more than or equal to 7 months. The performance score 2.0650.81 was significantly P0.0001 increased after treatment of the comorbidity compared to the performance score 1.1251.27 of patients without comorbidity. Only alkylating agents cyclophosphamide p0.003, Carboplatin  Oxaliplatin p 0.007, Cisplatin p 0.0001, and folic acid analogues Leucovorin p0.01 showed significant differences in the management of cancer between groups. This study suggests that breast cancer is associated with increased comorbidity burden compared to other types of cancer. Also, comorbidity is associated with overall decreased estimated survival rate and performance status among cancer patients.

 Many studies report the presence of comorbidities, which have a consequential impact on the management and survival of cancer patients. The aim of the present study is to assess the prevalence of comorbidities and their influence on overall management, estimated survival, and performance of cancer patients. A hospital based prospective study was conducted at a multi-specialty teaching hospital for a period of 10 months. Out of a sample of 140 cancer patients, 70 were diagnosed with comorbidities. Estimated survival rates and comorbidity scores were assessed using the Charlson Comorbidity Index CCI. Performance scores were observed using the Eastern Cooperative Oncology Group ECOG performance score. CCI and performance score were statistically analyzed by SPSS Version 19. Hypertension 40 was the leading comorbidity, followed by diabetes 25.71. Those women with high 5 CCI score 57.14, p0.04 had significantly decreased estimated survival rates of less than or equal to 2 months compared to those having less than  2 CCI score and who reached estimated survival rates of more than or equal to 7 months. The performance score 2.0650.81 was significantly P0.0001 increased after treatment of the comorbidity compared to the performance score 1.1251.27 of patients without comorbidity. Only alkylating agents cyclophosphamide p0.003, Carboplatin  Oxaliplatin p 0.007, Cisplatin p 0.0001, and folic acid analogues Leucovorin p0.01 showed significant differences in the management of cancer between groups. This study suggests that breast cancer is associated with increased comorbidity burden compared to other types of cancer. Also, comorbidity is associated with overall decreased estimated survival rate and performance status among cancer patients.

 Many studies report the presence of comorbidities, which have a consequential impact on the management and survival of cancer patients. The aim of the present study is to assess the prevalence of comorbidities and their influence on overall management, estimated survival, and performance of cancer patients. A hospital based prospective study was conducted at a multi-specialty teaching hospital for a period of 10 months. Out of a sample of 140 cancer patients, 70 were diagnosed with comorbidities. Estimated survival rates and comorbidity scores were assessed using the Charlson Comorbidity Index CCI. Performance scores were observed using the Eastern Cooperative Oncology Group ECOG performance score. CCI and performance score were statistically analyzed by SPSS Version 19. Hypertension 40 was the leading comorbidity, followed by diabetes 25.71. Those women with high 5 CCI score 57.14, p0.04 had significantly decreased estimated survival rates of less than or equal to 2 months compared to those having less than  2 CCI score and who reached estimated survival rates of more than or equal to 7 months. The performance score 2.0650.81 was significantly P0.0001 increased after treatment of the comorbidity compared to the performance score 1.1251.27 of patients without comorbidity. Only alkylating agents cyclophosphamide p0.003, Carboplatin  Oxaliplatin p 0.007, Cisplatin p 0.0001, and folic acid analogues Leucovorin p0.01 showed significant differences in the management of cancer between groups. This study suggests that breast cancer is associated with increased comorbidity burden compared to other types of cancer. Also, comorbidity is associated with overall decreased estimated survival rate and performance status among cancer patients.

 Many studies report the presence of comorbidities, which have a consequential impact on the management and survival of cancer patients. The aim of the present study is to assess the prevalence of comorbidities and their influence on overall management, estimated survival, and performance of cancer patients. A hospital based prospective study was conducted at a multi-specialty teaching hospital for a period of 10 months. Out of a sample of 140 cancer patients, 70 were diagnosed with comorbidities. Estimated survival rates and comorbidity scores were assessed using the Charlson Comorbidity Index CCI. Performance scores were observed using the Eastern Cooperative Oncology Group ECOG performance score. CCI and performance score were statistically analyzed by SPSS Version 19. Hypertension 40 was the leading comorbidity, followed by diabetes 25.71. Those women with high 5 CCI score 57.14, p0.04 had significantly decreased estimated survival rates of less than or equal to 2 months compared to those having less than  2 CCI score and who reached estimated survival rates of more than or equal to 7 months. The performance score 2.0650.81 was significantly P0.0001 increased after treatment of the comorbidity compared to the performance score 1.1251.27 of patients without comorbidity. Only alkylating agents cyclophosphamide p0.003, Carboplatin  Oxaliplatin p 0.007, Cisplatin p 0.0001, and folic acid analogues Leucovorin p0.01 showed significant differences in the management of cancer between groups. This study suggests that breast cancer is associated with increased comorbidity burden compared to other types of cancer. Also, comorbidity is associated with overall decreased estimated survival rate and performance status among cancer patients.

Article Details

Comorbidities and its relation to performance status and estimated survival rate among cancer patients

Authors:

N.A.

Publisher:

Marmara University

Main Topics:

Pharmaceutical Sciences | Clinical Pharmacology and Therapeutics | Basic Pharmacology

Journal:

Journal of Research in Pharmacy Vol.23 Issue 2, pp.304-314

Document Type:

Article

Publication Date:

6/2025

Document Language:

English

Document ID (Org No.):

2001346487

pISSN:

2630-6344

Cancer

comorbidity

estimated survival rate

treatment pattern

performance status

CCI

ECOG

Issues

Article Details

Authors: N.A.

Publisher: Marmara University

Main Topics: Pharmaceutical Sciences | Clinical Pharmacology and Therapeutics | Basic Pharmacology

Journal: Journal of Research in Pharmacy Vol.23 Issue 2, pp.304-314

Document Type: Article

Publication Date: 6/2025

Document Language: English

Document ID (Org No.): 2001346487

pISSN: 2630-6344

Issues

Authors:

N.A.

Publisher:

Marmara University

Main Topics:

Pharmaceutical Sciences | Clinical Pharmacology and Therapeutics | Basic Pharmacology

Journal:

Journal of Research in Pharmacy Vol.23 Issue 2, pp.304-314

Document Type:

Article

Publication Date:

6/2025

Document Language:

English

Document ID (Org No.):

2001346487

pISSN:

2630-6344